Compare Entegris Inc (ENTG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Zoetis Inc — how do they compare? Entegris Inc trades at $134.6 (market cap $21.12B), while Zoetis Inc trades at $77.27 (market cap $31.25B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| ENTG | ZTS | |
|---|---|---|
Market Cap | $21.12B | $31.25B |
Sector | Technology | Health |
52-Week High | $184.00 | $156.76 |
52-Week Low | $68.80 | $71.91 |
Enterprise Value | $24.44B | $38.54B |
Dividend Yield | 0.29% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $134.15, down 4.61% today, with technical indicators showing bearish momentum as the stock approaches key support at $133. The company maintains solid fundamentals with Q1 2026 earnings beating estimates at $0.86 per share and strong analyst consensus of 65% buy ratings. Recent developments include a $0.10 dividend declaration and new CFO appointment, while semiconductor industry tailwinds from AI-driven demand provide growth catalysts.
ENTG presents a compelling opportunity with 25% upside to the $178.40 consensus price target, supported by improving cash flow trends and semiconductor sector growth. However, elevated valuation multiples (P/E 80.17) and technical bearish signals warrant caution amid recent price volatility and competitive pressures in the semiconductor materials space.
Zoetis (ZTS) trades at $77.13, up 4.12% in the last session, with a bearish technical signal from moving averages. The company reported strong 2025 results, including $9.47B revenue and $2.67B net income, with high profitability margins. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU. Cash flow improved to a positive $325M in 2025, though net cash flow is projected to decline in 2026.
The stock presents a mixed outlook: strong fundamentals and a consensus price target of $101.43 suggest upside, but legal risks and bearish technicals pose near-term headwinds. Earnings momentum is key, with Q2 2026 results critical after a Q1 miss. Institutional sentiment is cautious despite no sell ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
